CHMP Backs the EU’s First Refillable Eye Implant

EMA's Committee for Medicinal Products for Human Use met 20–23 July 2026 and recommended a device-delivered medicine and a vaccine-composition update in the same sitting — one a genuine first for the EU market, the other a recurring but consequential piece of seasonal housekeeping. The committee adopted twelve positive opinions on new medicines, eight extensions of indication, three negative opinions, and one withdrawal.

A device and a drug, reviewed as one

Susvimo pairs ranibizumab, an anti-VEGF medicine already familiar from intravitreal injections, with a refillable implant that a surgeon inserts into the eye once and then tops up roughly every six months, rather than injecting the drug every four to eight weeks. CHMP's recommendation covers adults with neovascular (wet) age-related macular degeneration whose disease is stable after they have already responded to an intravitreal anti-VEGF medicine — a maintenance population, not first-line use. The committee's basis was a Phase 3, randomised, visual-assessor-masked, active-comparator study of 415 patients, which found the implant comparable to intravitreal ranibizumab dosed every four weeks, maintaining visual and anatomical outcomes. Reported side effects include iritis, conjunctival bleb or filtering-bleb leak, cataract, vitreous floaters, conjunctival haemorrhage, conjunctival hyperaemia, eye pain, and headache.

For a regulatory affairs team, the interesting part is less the ophthalmology than the file type: a medicine whose delivery mechanism is a surgically placed device is a combination-product question from the first regulatory strategy meeting onward, not a life-cycle add-on. CHMP's opinion is a recommendation, not the final word — it goes to the European Commission, which adopts the legally binding EU-wide marketing authorisation decision, ordinarily within about two months.

Four vaccines, one variant, one filing season

The more operationally urgent item for a larger number of companies is the strain update. CHMP gave a positive opinion to revise the antigenic composition of Comirnaty, Spikevax, Nuvaxovid, and Bimervax to target the XFG variant, aligning with the recommendation EMA's Emergency Task Force issued for the 2026/2027 vaccination campaign. Comirnaty and Spikevax move off LP.8.1, which EMA says is no longer in circulation; Nuvaxovid moves off JN.1; Bimervax's update is adapted specifically to the XFG.1.1 sublineage. Globally, EMA notes, roughly 80 percent of circulating variants still belong to the JN.1 lineage, with XFG remaining prevalent within it — the basis for betting the next campaign's vaccines on that target rather than a narrower descendant.

For manufacturers, a CHMP-recommended composition change is not optional paperwork: it is the trigger for the variation filings, updated batch releases, and revised product information that have to be in place before doses for the next campaign ship. Four sponsors now have the same variant, and the same clock, to work against — a pattern regulatory teams in the EU's device and vaccine ecosystem will recognize: a single committee decision propagating into parallel compliance deadlines across every affected manufacturer at once.

The rest of the docket

The meeting's other new-medicine recommendations included Lynavoy (linerixibat), an inhibitor of the ileal bile acid transporter recommended as the first medicine specifically for cholestatic pruritus — the intense itching caused by a build-up of bile acids — in adults with primary biliary cholangitis. Three applications for new medicines received negative opinions and one was withdrawn during the meeting; EMA's practice is to publish the underlying assessment reports once the procedure concludes. None of these decisions are final until the European Commission acts on them.